Refining Toxicity Testing through Advances in Human iPSC Technology



June 10, 2016

  • Share
  • Learn how advances in human induced pluripotent stem cell (iPSC) technology enable early detection and avoidance of neuro-, cardio-, and hepatotoxicity during drug development. The Cellular Dynamics line of iCell® products are fully differentiated human cells derived from iPSCs. iCell GlutaNeurons are a population of excitatory neurons that bring previously inaccessible human biology to the lab bench for both discovery and toxicity (seizurogenic) investigations. iCell Hepatocytes 2.0 maintain appropriate function longer than existing models and over extended culture periods, thus providing a relevant means for acute and sub-chronic toxicity testing in human tissue cells. iCell Cardiomyocytes2 exhibit electrical and contractile behavior that is translatable to both the human condition and more costly animal models. This webinar will provide examples from industry experts on how iPSC technology can have a meaningful impact on your day to day research. Speakers: Brad Swanson, PhD, Vice President, R&D: Cell Biology, Cellular Dynamics International Andrew Bruening-Wright, PhD, Principal Scientist, Charles River Laboratories William Proctor, PhD, DABT, Scientist, Investigative Toxicology, Department of Safety Assessment, Genentech

    Drug DiscoveryImaging/MicroscopyStem Cells

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.